A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes

Journal of Virology

Volumn 88, Issue 20, 2014, Pages 11802-11810

  Swanson, Kurt A ^a,c   Balabanis, Kara ^a   Xie, Yuhong ^a   Aggarwal, Yukti ^a   Palomo, Concepción ^b   Mas, Vicente ^b   Metrick, Claire ^a,d   Yang, Hui ^a,e   Shaw, Christine A ^a   Melero, José A ^b   Dormitzer, Philip R ^a   Carfi, Andrea ^a  

^a Novartis Vaccines Cambridge   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c SANOFI   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CYSTEINE; EPITOPE; FURIN; GLYCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOMER; MOTAVIZUMAB; NEUTRALIZING ANTIBODY; PROTEIN P27; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS FUSION PROTEIN VACCINE; VIRUS ANTIGEN;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE REARRANGEMENT; IMMUNOGENICITY; NONHUMAN; OLIGOMERIZATION; POINT MUTATION; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; REACTION ANALYSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS NEUTRALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; PROTEIN DEGRADATION;

ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; EPITOPES; HUMANS; PROTEOLYSIS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84907916697     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01225-14     Document Type: Article

References (21)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. Hall CB. 2010. Respiratory syncytial virus, p 2207-2221. In Mandell GL Bennett JE, Dolin R (ed), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Churchill Livingstone, New York, NY.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186. http://dx.doi.org /10.1001/jama.289.2.179.
4. Han LL, Alexander JP, Anderson LJ. 1999. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179:25-30. http://dx.doi.org/10.1086/314567.
5. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224. http://dx.doi.org/10.1086/514115.
6. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
7. Anderson R, Huang Y, Langley JM. 2010. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol. 5:585-602. http://dx.doi.org/10.2217/fmb.10.22.
8. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl. Acad. Sci. U. S. A. 108:9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
9. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
10. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85:7788-7796. http: //dx.doi.org/10.1128/JVI.00555-11.
11. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http://dx.doi.org/10.1126/science.1243283.
12. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C. 2012. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl. Acad. Sci. U. S. A. 109: 3089-3094. http://dx.doi.org/10.1073/pnas.1115941109.
13. Yin HS, Paterson RG, Wen X, Lamb RA, Jardetzky TS. 2005. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc. Natl. Acad. Sci. U. S. A. 102:9288-9293. http://dx.doi.org/10.1073/pnas.0503989102.
14. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS. 2006. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38-44. http://dx.doi.org/10.1038/nature04322.
15. Swanson K, Wen X, Leser GP, Paterson RG, Lamb RA, Jardetzky TS. 2010. Structure of the Newcastle disease virus F protein in the post-fusion conformation. Virology 402:372-379. http://dx.doi.org/10.1016/j.virol.2010.03.050.
16. González-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez JA, Albar JP, Skehel JJ, Wiley DC, Melero JA. 2001. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl. Acad. Sci. U. S. A. 98:9859-9864. http://dx.doi.org/10.1073/pnas.151098198.
17. Sastre P, Melero JA, Garcia-Barreno B, Palomo C. 2005. Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J. Med. Virol. 76:248-255. http://dx.doi.org/10.1002/jmv.20349.
18. Anderson LJ, Bingham P, Hierholzer JC. 1988. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J. Virol. 62:4232-4238.
19. Martinez I, Melero JA. 1998. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J. Gen. Virol. 79:2215-2220.
20. Connolly SA, Leser GP, Yin HS, Jardetzky TS, Lamb RA. 2006. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc. Natl. Acad. Sci. U. S. A. 103:17903-17908. http://dx.doi.org/10.1073/pnas.0608678103.
21. Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122-131. http://dx.doi.org/10.1006/viro.2000.0279.